Precigen (NASDAQ:PGEN) Stock Rating Raised to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Precigen (NASDAQ:PGEN) from a buy rating to a strong-buy rating in a research report report published on Sunday morning,Wall Street Zen reports.

Several other equities research analysts have also recently commented on PGEN. Zacks Research cut shares of Precigen from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Raymond James Financial set a $12.00 price target on shares of Precigen in a research report on Thursday. Citigroup reissued a “market outperform” rating on shares of Precigen in a research note on Thursday. HC Wainwright increased their price target on shares of Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, B. Riley Financial assumed coverage on shares of Precigen in a report on Friday, September 25th. They issued a “buy” rating and a $12.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Precigen Stock Performance

Shares of PGEN stock opened at $4.47 on Friday. The stock has a fifty day moving average of $6.98 and a 200 day moving average of $5.28. Precigen has a 52 week low of $3.04 and a 52 week high of $8.98. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of 44.70 and a beta of 1.01. The company has a quick ratio of 4.83, a current ratio of 5.58 and a debt-to-equity ratio of 1.12.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The business had revenue of $74.15 million for the quarter, compared to the consensus estimate of $71.55 million. Precigen had a net margin of 15.55% and a return on equity of 57.93%. The company’s quarterly revenue was up 2437.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.06) EPS. As a group, research analysts expect that Precigen will post 0.27 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Rutul R. Shah sold 15,342 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $7.50, for a total transaction of $115,065.00. Following the completion of the transaction, the chief operating officer directly owned 468,865 shares in the company, valued at $3,516,487.50. This trade represents a 3.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey B. Kindler sold 185,000 shares of Precigen stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.44, for a total value of $1,376,400.00. Following the completion of the transaction, the director directly owned 17,100 shares of the company’s stock, valued at approximately $127,224. This represents a 91.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 235,000 shares of company stock worth $1,751,400. Insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Corient Private Wealth LP purchased a new position in Precigen in the 2nd quarter worth approximately $1,908,000. The Manufacturers Life Insurance Company purchased a new stake in Precigen during the 2nd quarter valued at $519,000. Bank of New York Mellon Corp purchased a new stake in Precigen during the 2nd quarter valued at $2,705,000. Bank of America Corp DE purchased a new stake in Precigen during the 2nd quarter valued at $10,536,000. Finally, Squarepoint Ops LLC boosted its stake in Precigen by 462.8% during the 2nd quarter. Squarepoint Ops LLC now owns 353,272 shares of the biotechnology company’s stock valued at $2,014,000 after purchasing an additional 290,505 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors.

Key Stories Impacting Precigen

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts for Precigen across Q4 2026 and each quarter of 2027, while maintaining a Buy rating and an $18 price target. HC Wainwright estimates and rating
• Positive Sentiment: Citizens JMP raised its price target from $11 to $12 and reiterated a Market Outperform rating, adding to the bullish analyst outlook. Citizens JMP price target
• Positive Sentiment: Precigen’s Q3 revenue of $74.1 million topped the cited FactSet estimate of $71.5 million. The reported $0.08 per-share earnings beat some estimates but fell short of the higher Zacks consensus, making the earnings picture mixed. Q3 revenue results
• Negative Sentiment: A valuation analysis argues that PGEN may already be fully priced based on current earnings, which could limit further upside if future growth does not meet expectations. Precigen valuation analysis

About Precigen

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.